Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia by Esperanza Such, Ulrich Germing, Luca Malcovati,

Slides:

Advertisements

Similar presentations

Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD by Attilio.

Advertisements

Spliceosome mutations in myeloid neoplasms

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka,

The genetic basis of myelodysplasia and its clinical relevance

High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass by Grace M. Lee, Ian J. Welsby,

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.

Thrombophilia and outcomes of assisted reproduction technologies: a systematic review and meta-analysis by Marcello Di Nisio, Anne W. S. Rutjes, Noemi.

A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability.

Single-Unit Umbilical Cord Blood Transplantation from Unrelated Donors in Adult Patients with Chronic Myelogenous Leukemia Jaime Sanz, Pau Montesinos,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts by Luca Malcovati, Mohsen Karimi, Elli Papaemmanuil, Ilaria.

Single-Unit Umbilical Cord Blood Transplantation from Unrelated Donors in Adult Patients with Chronic Myelogenous Leukemia Jaime Sanz, Pau Montesinos,

Experimental Hematology

EBV DNA: a Hodgkin lymphoma biomarker?

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup by Marie-Anne Hospital, Thomas Prebet,

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

Gupta V, Tallman MS, Weisdorf DJ

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study by Yu Wang, Qi-Fa Liu, Lan-Ping Xu, Kai-Yan Liu,

Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.

Tax fingerprint in adult T-cell leukemia

One giant leap for pediatric AMKL

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Nonmyeloablative conditioning for relapsed follicular lymphoma

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.

Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis by José Fos, Thomas Pabst, Vibor Petkovic,

Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia:

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous.

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study by Neil P. Shah, François.

Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In.

CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but.

by Alexander Röth, Andreas Hüttmann, Russell P

The genetic basis of myelodysplasia and its clinical relevance

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.

Imatinib (IM) Plus Thalidomide (Thali), A Effective Combination For The Treatment Of Chronic Myeloid Leukemia (CML) Philadelphia ChromosomePositive (Ph.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score by Ollivier Legrand, Jean-Yves Perrot, Marion Baudard, Annie.

Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies by Sabine Kayser, Manuela Zucknick,

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory.

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes by Raphael Itzykson, Simon Crouch, Erica Travaglino, Alex Smith,

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Chronic graft-versus-host disease

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia by Jaime Sanz, Mi Kwon, Guiomar Bautista, Miguel.

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories by Sanam Loghavi, Dawen Sui, Peng Wei, Guillermo Garcia-Manero, Sherry.

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients by Alan K. Burnett,

Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte.

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge.

Effect of CD8+ Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies Federico Moscardó, Jaime Sanz, Francisco.

Revised International Prognostic Scoring System for Myelodysplastic Syndromes by Peter L. Greenberg, Heinz Tuechler, Julie Schanz, Guillermo Sanz, Guillermo.

A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation Philippe Armand, Haesook.

Impact of age on clinical risk scores in follicular lymphoma

Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations by Ami B. Patel, Erin M. Pettijohn,

Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11.

by Jan J. Cornelissen, and Didier Blaise

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia

Presentation transcript:

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia by Esperanza Such, Ulrich Germing, Luca Malcovati, José Cervera, Andrea Kuendgen, Matteo G. Della Porta, Benet Nomdedeu, Leonor Arenillas, Elisa Luño, Blanca Xicoy, Mari L. Amigo, David Valcarcel, Kathrin Nachtkamp, Ilaria Ambaglio, Barbara Hildebrandt, Ignacio Lorenzo, Mario Cazzola, and Guillermo Sanz Blood Volume 121(15):3005-3015 April 11, 2013 ©2013 by American Society of Hematology

Outcomes according to the CPSS in the training cohort. Outcomes according to the CPSS in the training cohort. Unadjusted actuarial probability of (A) OS (P < .001) and (B) risk of AML transformation (P < .001). Esperanza Such et al. Blood 2013;121:3005-3015 ©2013 by American Society of Hematology

Outcomes according to the CPSS in the validation cohort. Outcomes according to the CPSS in the validation cohort. Unadjusted actuarial probability of (A) OS (P < .001) and (B) risk of AML transformation (P < .001). Esperanza Such et al. Blood 2013;121:3005-3015 ©2013 by American Society of Hematology